Drug intelligence / Profile preview

capecitabine + ramucirumab

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Capecitabine + ramucirumab is a combination therapy that pairs capecitabine, an oral fluoropyrimidine chemotherapy agent, with ramucirumab, a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. This combination has been studied primarily in gastrointestinal cancers, including advanced esophagogastric adenocarcinoma and metastatic colorectal cancer. The PLATFORM study demonstrated significant improvements in progression-free survival and overall survival when used as maintenance therapy in patients with advanced esophagogastric adenocarcinoma following platinum-based chemotherapy.

Other names: cape-ram

Targets

TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on capecitabine + ramucirumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on capecitabine + ramucirumab.

Explore the full profile